Teva denies outgoing CEO board role

Against his expressed wishes, Schultz will not gain a seat on the board at the Israeli pharmaceutical firm when he steps down as CEO at year-end.

Teva and Schultz have not come to an agreement on a potential board seat for the outgoing CEO | Photo: Ida Munch

Danish national Kåre Schultz’s time at the helm of Teva draws to a close at year-end, and his hope to continue serving the Israeli pharmaceutical company as a board member has just been shot down.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs